Anticoagulation and antiplatelet therapy in short bowel syndrome: A systematic review

Background Short bowel syndrome (SBS) is one cause of intestinal insufficiency or failure. Drug therapy may be difficult in this patient group at least in part due to abnormalities in anatomy or surface area for absorption. Anticoagulation may be indicated due to the underlying cause of SBS or to treat complications of parenteral support. Aims To review the literature on the use of anticoagulation and antiplatelet agents in SBS. Methods Systematic literature search in MEDLINE, EMBASE and the Cochrane library for studies pertaining to SBS, anticoagulants and antiplatelets to 22nd February 2024. Results 24 of 725 screened articles met the eligibility criteria. The majority were case reports or series with no randomised controlled trials. Warfarin was the most studied anticoagulant with adequate anticoagulation with gut lengths as short as 12 cm. Rivaroxaban was the most studied DOAC with target plasma concentrations achieved with as little as 30 cm intestine. Apixaban was studied in one case with target plasma concentrations reached and no recurrent thrombosis or bleeding events. Dabigatran was not shown to reliably achieve target plasma concentrations. Minimal data was available on antiplatelet agents in short bowel syndrome with no long term clinical outcomes reported. Conclusions The literature is largely limited to case reports and series. Warfarin is the most widely studied anticoagulant in SBS and is effective. Absorption of rivaroxaban and, probably, apixaban is adequate in SBS but longer term studies on clinical outcomes are needed. Insufficient data is available to make firm recommendations for antiplatelet therapy.

• Publication year

  2024

• Venue

  Intestinal Failure

• Publication date

  2024-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.intf.2024.100007PMID 41646114PMCID 12851339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Quality of warfarin anticoagulation in adults with short bowel syndrome on home parenteral nutrition.

  2022cited by this paper
• The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

  2021cited by this paper
• Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.

  2020cited by this paper
• Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports

  2020cited by this paper
• Aspirin

  2019cited by this paper
• Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

  2019cited by this paper
• Population Pharmacokinetics of Apixaban in Subjects With Nonvalvular Atrial Fibrillation

  2018cited by this paper
• Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects

  2018influential reference
• Comparison of light transmission aggregometry and multiple electrode aggregometry for the evaluation of patients with mucocutaneous bleeding

  2018cited by this paper
• Warfarin Absorption in Short Bowel Syndrome

  2018cited by this paper
• Oral Anticoagulant Use After Bariatric Surgery: A Literature Review and Clinical Guidance.

  2017cited by this paper
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

  2017cited by this paper
• Pharmacokinetics of dabigatran etexilate and rivaroxaban in patients with short bowel syndrome requiring parenteral nutrition: The PDER PAN study.

  2017influential reference
• Anticoagulants for the prevention and treatment of catheter-related thrombosis in adults and children on parenteral nutrition: a systematic review and critical appraisal.

  2017cited by this paper
• Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome.

  2017cited by this paper
• How I use laboratory monitoring of antiplatelet therapy.

  2017cited by this paper
• Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs)

  2017influential reference
• ESPEN endorsed recommendations. Definition and classification of intestinal failure in adults.

  2015cited by this paper
• Pros and Cons of Vitamin K Antagonists and Non–Vitamin K Antagonist Oral Anticoagulants

  2015cited by this paper
• Rivaroxaban as anticoagulant therapy in short bowel syndrome. Report of three cases.

  2015influential reference
• Individualised dual antiplatelet therapy in a patient with short bowel syndrome after acute myocardial infarction with coronary artery stenting

  2015influential reference
• Absorption and Efficacy of Acetylsalicylic Acid in Patients With Short Bowel Syndrome

  2014cited by this paper
• Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry?

  2014influential reference
• Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome

  2014influential reference
• Pros and cons of new oral anticoagulants.

  2013cited by this paper
• Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects.

  2013influential reference
• Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

  2013influential reference
• Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties

  2013cited by this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants

  2013cited by this paper
• Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

  2012influential reference
• Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

  2012cited by this paper
• Effect of Multiple Doses of Omeprazole on the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Rivaroxaban

  2011cited by this paper
• P2Y12 platelet inhibition in clinical practice

  2011cited by this paper
• 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease

  2010cited by this paper
• Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin.

  2010cited by this paper
• Monitoring plasma heparin concentration in a patient with antiphospholipid syndrome

  2010influential reference
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009influential reference
• Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate

  2008influential reference
• Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement

  2008cited by this paper
• Sublingual administration of warfarin: a novel form of delivery

  2008influential reference
• Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

  2007cited by this paper
• A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.

  2007cited by this paper
• Effect of Food, an Antacid, and the H2 Antagonist Ranitidine on the Absorption of BAY 59–7939 (Rivaroxaban), an Oral, Direct Factor Xa Inhibitor, in Healthy Subjects

  2006cited by this paper
• Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement

  2005cited by this paper
• Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro

  2005cited by this paper
• Warfarin Resistance in a Patient with Short Bowel Syndrome

  1998influential reference
• Oral Anticoagulation in Patients with Short-Bowel Syndrome

  1990influential reference
• Oral anticoagulant therapy in patients who require nutritional support.

  1987cited by this paper
• Warfarin resistance associated with intravenous lipid administration.

  1987cited by this paper
• Warfarin resistance in a patient with short-bowel syndrome.

  1987cited by this paper
• Bioavailability of warfarin in a patient with severe short bowel syndrome.

  1986cited by this paper
• Warfarin absorption after massive small bowel resection.

  1985cited by this paper
• Warfarin absorption in a patient with short-bowel syndrome.

  1985influential reference
• Successful oral anticoagulant therapy in a patient with short bowel syndrome.

  1977influential reference

• Updates on intestinal failure management.

  2026cites this paper
• Rivaroxaban vs. Apixaban in Short bowel syndrome: a focused clinical Pharmacology review.

  2026cites this paper
• Absorption and anticoagulant management of rivaroxaban in patients with short bowel syndrome.

  2025cites this paper
• Prophylaxis or peril? Rethinking catheter-related thrombosis prevention in home parenteral nutrition.

  2025cites this paper